Nonalcoholic fatty liver disease.
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the United States and, indeed, worldwide. It has become a global public health issue. In the United States, the prevalence in the general population is estimated at approximately 20%, while that in the morbidly obese population at approximately 75-92% and in the pediatric population at approximately 13-14%. The progressive form of NAFLD, nonalcoholic steatohepatitis, is estimated at approximately 3-5%, with approximately 3-5% of these having progressed to cirrhosis. Thus, the numbers of individuals at risk for end-stage liver disease and development of primary liver cancer is large. NAFLD is an independent risk factor for cardiovascular disease, leads to increased all-cause mortality, and to increased liver-related mortality. This review focuses on recent advances in our understanding of the NAFLD disease spectrum, including etiology, diagnosis, treatment, and genetic and environmental risk factors and suggests future directions for research in this important area.
Erickson
Sandra K
SK
Department of Medicine, University of California, Veterans Affairs Medical Center, San Francisco, CA 94121, USA. sandra.kerickson@ucsf.edu
D000438:Alcohols; D000818:Animals; D004195:Disease Models, Animal; D005234:Fatty Liver / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000378:metabolism*; D006801:Humans
D000438:Alcohols